Breast Cancer News and Research

Latest Breast Cancer News and Research

Court rules in favor of Eli Lilly for Evista's method-of-use patents

The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's (NYSE: LLY) method-of-use patents on Evista(R) (raloxifene HCl tablets). In the case of Eli Lilly and Company v. Teva Pharmaceuticals Industries Ltd., the court ruled in favor of Lilly on all accounts for these method-of-use patents, including the patent doctrines of obviousness, enablement, and inequitable conduct.

24 Sep 2009

Cook Medical launches next-generation IVC filter delivery system for treating pulmonary embolism

Physicians can now navigate even the most tortuous anatomy with greater speed and safety with the next-generation inferior vena cava (IVC) filter delivery system introduced today by Cook Medical at TCT 2009. The release of the NavAlign™ delivery system marks the 20th anniversary of Cook’s first IVC filter and further advances the treatment of pulmonary embolism (PE), a life-threatening condition caused by blood clots in the lungs that affects thousands of Americans annually.

24 Sep 2009

BREVAGen test offers precise breast cancer risk assessment

Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGen™ breast cancer risk stratification test is now clinically available in select U.S. markets. Perlegen plans to add sales areas to make the test available nationwide over the next few months.

24 Sep 2009

Advanced Biohealing announces growth strategy to expand its product line

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced a strategic growth plan designed to continue the transformation of this former start-up into the leading international regenerative medicine company.

24 Sep 2009

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High Intensity Focused Ultrasound) as a combination therapy to non-invasively treat difficult cancers has successfully completed the feasibility stage.

23 Sep 2009

Interactive campaign to raise awareness on breast cancer

This week, Yoplait, in partnership with Susan G. Komen for the Cure, launched Know Your Girls, an interactive campaign that empowers young women to learn about breast cancer risk factors -- and then share this knowledge with their circle of friends.

23 Sep 2009

ART's new generation Optix MX3 optical molecular imaging system unveiled

ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today unveiled a new generation of its optical molecular imaging system, called Optix® MX3, at the Industry Workshop opening event of the World Molecular Imaging Congress.

23 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

23 Sep 2009

GE Healthcare creates a digital wall to commemorate the tenth anniversary of digital mammography

In addition to being Breast Cancer Awareness Month, this October is the tenth anniversary of digital mammography, a technology introduced by GE Healthcare (NYSE:GE) in 1999. Similar to digital photography, digital mammography replaces the film used in traditional mammography with digital files viewed and stored on computers.

23 Sep 2009

ESMO recognises outstanding achievements of leading cancer specialists

The European Society for Medical Oncology (ESMO) has recognized the outstanding achievements of three leading cancer specialists with its three prestigious annual awards: the 2009 ESMO Award, Hamilton Fairley Award and ESMO Lifetime Achievement Award.

23 Sep 2009

Ambassador Nancy G. Brinker calls for a global fight against cancer

The leader of the global breast cancer movement today warned of a coming wave of cancer deaths and told global health ministers to be “fearless and united” in addressing the growing cancer crisis, particularly in developing countries.

23 Sep 2009

Breast cancer awareness campaign launched by Samsung Electronics Europe

Samsung Electronics Europe has launched ‘Everybody’s Doing It’, an online campaign and website which is a call to action encouraging women in Europe to check for breast cancer and prevent the disease from spreading. By visiting www.morethantalk.eu women can find an instant community of support, a place to make pledges to raise further awareness and a place to view or forward a short viral movie called ‘Everybody’s Doing It’; containing footage of eight women whose lives have been affected by breast cancer. The viral is intended to reach over 400,000 women - more than the number who are diagnosed with breast cancer in Europe every year.

23 Sep 2009

Results of IES presented at ECCO

Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events. In addition, IES showed that AROMASIN prolonged overall survival (OS) in the ER+/unknown population with a 14% reduction in the risk of dying. These results demonstrate that the benefits of treatment are maintained in long term follow-up. These results were presented at the joint ECCO 15/ESMO 34 meeting in Berlin, Germany.

23 Sep 2009

NIH grants $3.4M to develop tools for identification of prostate cancer using MRI

Rutgers University and two collaborators have received a $3.4 million research grant to develop tools aimed at improving the identification of prostate cancer using MRI, or magnetic resonance imaging.

23 Sep 2009

Decision Points helps patients with important medical decisions

Healthwise has released a new, interactive generation of its Decision Points to help people make better decisions with their doctors.

23 Sep 2009

FCI to educate women about fertility preservation

Life-saving cancer treatments such as chemotherapy and radiation can destroy the reproductive potential of both men and women; an added struggle for the 130,000 people in the US diagnosed with cancer each year. The good news is that advances in fertility technologies now give patients the ability to preserve their fertility prior to treatment, an option many oncologists fail to inform their patients.

23 Sep 2009

Gamma Medica-Ideas closes $24 million financing to support digital technologies

Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital molecular imaging systems, announced today that it had closed a $24 million financing, the company's first institutional round, in order to support continued growth of the company's proprietary digital SPECT, PET and CT technologies in current and new markets.

23 Sep 2009

Oncotype DX Recurrence Score provides consistent results across varied patient populations

Genomic Health, Inc. today, announced results from the first study to compare the distribution of Oncotype DX® Recurrence Score® results between European, Middle Eastern and United States patient populations.

22 Sep 2009